BioSpace News Archive

IMIDomics, Inc. announced the formation of an Immunology Advisory Board consisting of a number of scientific and industry luminaries with experience in developing and bringing to market new therapies targeting IMIDs.

CMC Pharmaceuticals has been awarded a Sequential Phase II Small Business Innovation Research (“SBIR”) grant from the U.S. Defense Department’s (“DoD”) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Threat Reduction Agency.

Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology today announced its intention to study the potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in immunocompromised patients.

Hoag’s innovative spine team has performed the first spinal fusion surgery utilizing the recently FDA-cleared augmented reality surgical navigator for Spine, co-developed by neurosurgeons from Hoag’s Pickup Family Neurosciences Institute and medical visualization platform leader Surgical Theater.

City of Hope announced it has received, along with other leading cancer centers, an $8 million Therapy ACceleration To Intercept CAncer Lethality award from the Prostate Cancer Foundation to develop clinic-ready chimeric antigen receptor T cell therapies for advanced prostate cancer that can overcome the therapy’s current limitations.

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that an abstract relating to its ongoing Phase 2 myelofibrosis trial (MYLOX-1) has been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from the ongoing dose-escalation stage of its Phase 1/2 clinical trial of KB-0742, the company’s cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified and transcriptionally addicted solid tumors, support a recommended Phase 2 dose (RP2D) of 60 mg.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that the company’s management team will provide a corporate update on Sunday, December 11, 2022, at 10:00 AM EST / 9:00 CST, in conjunction with poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, LA.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.